Results 141 to 150 of about 118,635,816 (237)

Red lines and green lights: Gene therapy for inherited erythroid disorders beyond the haemoglobinopathies

open access: yesBritish Journal of Haematology, Volume 209, Issue 4, Page 1469-1481, October 2026.
Gene therapy is revolutionizing treatment paradigms for haemoglobinopathies, establishing a translational framework for disorders that impact red blood cell development. In their paper, Joshi et al. describe the preclinical and early clinical landscape of gene therapies for non‐haemoglobinopathy erythroid disorders and highlight common thematic ...
Gaurav Joshi   +3 more
wiley   +1 more source

Investigating the Distribution: Signal, Noise, and the Resolution Toolkit in Evidence‐Based Medicine

open access: yesJournal of Evaluation in Clinical Practice, Volume 32, Issue 7, October 2026.
ABSTRACT Rationale, Aims and Objectives Evidence‐based medicine (EBM) manages observational noise but lacks an explicit framework for taxonomic blur: treatment‐relevant variation generated when syndromic populations mix patients differing in mechanism or treatment responsiveness. Patients present with syndromes, not resolved pathophysiological classes.
Frederick Arthur
wiley   +1 more source

Cyclosporine treatment of acquired hemophilia due to factor VIII antibodies [PDF]

open access: yes, 2000
Acquired hemophilia, caused by autoantibodies against coagulation factor VIII, is usually treated with steroids, cyclophosphamide, intravenous gammaglobulins and sporadically other drugs.
Baele, Gaston   +2 more
core  

Postpartum Acquired Hemophilia

open access: yesNihon Naika Gakkai Zasshi, 2007
Miyahira, Takeshi   +3 more
openaire   +3 more sources

An Automated Microfluidic System for Haemostasis Assessment in Cirrhosis With Thrombocytopenia

open access: yesLiver International, Volume 46, Issue 10, October 2026.
ABSTRACT Background & Aims Conventional laboratory tests do not capture platelet–vessel wall interactions (primary haemostasis) occurring in vivo, limiting guidance before invasive procedures. This is relevant in patients with thrombocytopenia, hallmark of advanced cirrhosis. Microfluidic assays may overcome these limitations.
Niccolò Bitto   +14 more
wiley   +1 more source

Cryoprecipitate utilisation, shortages and institutional policies in the United States: A survey of practices and policies

open access: yesTransfusion Medicine, Volume 36, Issue 5, Page 503-510, October 2026.
Abstract Background Since the COVID‐19 pandemic, demand for blood products has remained high, while donations have declined. Institutional policies guiding the use of these products may affect their availability, utilisation and waste. We surveyed blood banks (BBs) in the United States (U.S.) to assess policies and practices related to cryoprecipitate ...
Chinelo P. Onyenekwu   +3 more
wiley   +1 more source

No evidence of hypercoagulability, altered fibrinolysis, or increased fibrin(ogen) microaggregates in never‐hospitalized long COVID

open access: yes
HemaSphere, Volume 10, Issue 10, October 2026.
Emily Fraser   +18 more
wiley   +1 more source

Acquired hemophilia A

open access: yesTenri Medical Bulletin, 2013
Maesako, Yoshitomo   +2 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy